PCRX — Pacira BioSciences, Inc.
$36.46
+$0.00 (+0.00%)
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve.
Market Cap
$1.46B
Forward P/E
10.4x
52-Week Range
N/A
PCRX Price History
Revenue vs. Net Income
$726M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$137M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
2.8%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.2x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
2.1%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
-2.6%
Net buyback · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
